0001597264false00015972642020-12-172020-12-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): December 17, 2020

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

Delaware

 

001-37359

 

26-3632015

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 45 Sidney Street

Cambridge, Massachusetts

 

02139

(Address of principal executive offices)

 

(Zip Code)

 Registrant’s telephone number, including area code: (617) 374-7580

 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

BPMC

Nasdaq Global Select Market

Item 8.01 Other Events. 

On December 17, 2020, Blueprint Medicines Corporation (the “Company”) issued a press release announcing the submission of a supplemental new drug application (“sNDA”) to the U.S. Food and Drug Administration (“FDA)” for AYVAKIT™ (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis. The Company has requested priority review for the sNDA, which, if granted, could result in a six-month review process. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press release issued by Blueprint Medicines Corporation on December 17, 2020

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

2

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

BLUEPRINT MEDICINES CORPORATION

 

 

 

 

 Date: December 17, 2020

By:

/s/ Jeffrey W. Albers

 

 

Jeffrey W. Albers

 

 

Chief Executive Officer

3